Home > Gastroenterology > No benefit to adding trastuzumab to neoadjuvant chemoradiation for HER2 esophageal cancer

No benefit to adding trastuzumab to neoadjuvant chemoradiation for HER2 esophageal cancer


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
The Lancet Oncology
Reuters Health - 27/01/2022 - In patients with HER2-overexpressing esophageal cancer, adding trastuzumab to neoadjuvant chemoradiation was not effective in a phase 3 trial.  HER2-positive esophagogastric cancer "does not behave the same way as HER2-positive breast cancer, (and) agents active in breast cancer (don't have) the same activity in esophagogastric cancer," Dr. David Ilson of Memorial Sloan Kettering Cancer Center in New York City told Reuters Health by email.  "Although disappointing, the negative results of this trial indicate two things," he said. "One, trastuzumab is insufficient by itself to improve outcome in locally advanced HER2-positive esopha...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on